ArticleCancers2024

Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation.

Mioko Matsuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.